title: Von Willebrand factor containing factor VIII concentrates.
abstract: There are several plasma derived von Willebrand factors (vWF) containing factor (FVIII) concentrates that can be used in the treatment of von Willebrand disease (vWD). All concentrates are effective in attaining normal postinfusion levels or of FVIII:C but it is difficult to achieve normalization of the bleeding time even with concentrates containing almost all vWF multimers including those of high molecular weight. Haemate P (Centeon) may be considered as the golden standard concentrate available at present. However, the development of more purified vWF concentrates devoid of FVIII:C is the goal for future development.
authors: Department for Coagulation Disorders, University of Lund, University Hospital, Malmö, Sweden. erik.berntorp@medforsk.mas.lu.se
authors: E
authors: E
authors: Berntorp
mesh_terms: D005169:Factor VIII / Q000737:chemistry* / Q000627:therapeutic use; D006801:Humans; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use; D014842:von Willebrand Diseases / Q000188:drug therapy; D014841:von Willebrand Factor / Q000737:chemistry* / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D014841:von Willebrand Factor; D005169:Factor VIII